tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders StocksMarket MoversTipRanks 50 IndexAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksFDA CalendarMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsGlossaryFAQs
About Us
About TipRanksContact UsReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
FDA Calendar
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Private Companies
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Advertisement
Advertisement

MNKD Stock Latest News

MannKind initiated with a Buy at Truist
The FlyMannKind initiated with a Buy at Truist
5d ago
MNKD
MannKind price target lowered to $10 from $15 at Oppenheimer
PremiumThe Fly
MannKind price target lowered to $10 from $15 at Oppenheimer
18d ago
MNKD
MannKind’s Strategic Advancements and Product Potential Justify Buy Rating Despite MNKD-101 Discontinuation
PremiumRatings
MannKind’s Strategic Advancements and Product Potential Justify Buy Rating Despite MNKD-101 Discontinuation
18d ago
MNKD
Midday Fly By: Insurers slip as Senate spending bill lacks ACA extension
PremiumThe Fly
Midday Fly By: Insurers slip as Senate spending bill lacks ACA extension
18d ago
JD
CNC
H.C. Wainwright remains bullish on MannKind despite disappointing MNKD-101 news
PremiumThe Fly
H.C. Wainwright remains bullish on MannKind despite disappointing MNKD-101 news
18d ago
MNKD
MannKind’s Resilience and Growth Potential: A Buy Rating Amid Setbacks and Opportunities
PremiumRatingsMannKind’s Resilience and Growth Potential: A Buy Rating Amid Setbacks and Opportunities
18d ago
MNKD
MannKind Halts Phase 3 Trial for MNKD-101
Premium
Company Announcements
MannKind Halts Phase 3 Trial for MNKD-101
19d ago
8K
MNKD
MannKind provides update on Phase 3 ICoN-1 trial of nebulized clofazimine
Premium
The Fly
MannKind provides update on Phase 3 ICoN-1 trial of nebulized clofazimine
19d ago
MNKD
MannKind Corporation Reports Strong Q3 2025 Growth
PremiumCompany Announcements
MannKind Corporation Reports Strong Q3 2025 Growth
23d ago
MNKD
MannKind’s Record Q3 2025 Earnings and Strategic Moves
PremiumCompany Announcements
MannKind’s Record Q3 2025 Earnings and Strategic Moves
23d ago
MNKD
MannKind’s Strategic Initiatives and Partnerships Signal Strong Growth Potential
PremiumRatings
MannKind’s Strategic Initiatives and Partnerships Signal Strong Growth Potential
23d ago
MNKD
MannKind’s Strong Financial Performance and Growth Prospects Drive Buy Rating
PremiumRatings
MannKind’s Strong Financial Performance and Growth Prospects Drive Buy Rating
23d ago
MNKD
MannKind reports Q3 EPS 7c, consensus 3c
PremiumThe FlyMannKind reports Q3 EPS 7c, consensus 3c
24d ago
MNKD
MNKD Earnings this Week: How Will it Perform?
Premium
Pre-Earnings
MNKD Earnings this Week: How Will it Perform?
26d ago
MNKD
Strong Revenue Growth and Strategic Developments Support MannKind’s Buy Rating
Premium
Ratings
Strong Revenue Growth and Strategic Developments Support MannKind’s Buy Rating
30d ago
MNKD
MannKind’s Afrezza: Promising Expansion and Growth Potential with FDA sBLA Acceptance
PremiumRatings
MannKind’s Afrezza: Promising Expansion and Growth Potential with FDA sBLA Acceptance
2M ago
MNKD
MannKind announces U.S. FDA accepted sBLA for Afrezza Inhalation Powder
PremiumThe Fly
MannKind announces U.S. FDA accepted sBLA for Afrezza Inhalation Powder
2M ago
MNKD
MannKind Completes Acquisition of scPharma
PremiumCompany Announcements
MannKind Completes Acquisition of scPharma
2M ago
8K
MNKD
MannKind completes acquisition of scPharmaceuticals
PremiumThe Fly
MannKind completes acquisition of scPharmaceuticals
2M ago
MNKD
SCPH
Buy Rating for MannKind Supported by Strong Tyvaso Efficacy in IPF Treatment
PremiumRatingsBuy Rating for MannKind Supported by Strong Tyvaso Efficacy in IPF Treatment
2M ago
MNKD
MannKind names Dr. Ajay Ahuja as Chief Medical Officer
Premium
The Fly
MannKind names Dr. Ajay Ahuja as Chief Medical Officer
2M ago
MNKD
MannKind Corporation’s Phase 3 Study: A Potential Game-Changer for Nontuberculous Mycobacterial Infections
Premium
Company Announcements
MannKind Corporation’s Phase 3 Study: A Potential Game-Changer for Nontuberculous Mycobacterial Infections
3M ago
MNKD

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >